Case Study: G3 Pharmaceuticals secures funding confidence with Clarivate Derwent patent analytics

Comprehensive patent landscape analysis transforms the IP due diligence process

G3 Pharmaceuticals, a US-based development-stage biopharmaceutical company focused on galectin-3 inhibitors for serious medical conditions, needed to prepare for its first funding round and answer investor questions about intellectual property ownership, freedom to operate, and patent risk. The company turned to Clarivate’s Derwent Patent Analytics and Derwent Innovation tools to better understand the complex galectin-3 patent landscape and strengthen its IP due diligence process.

Clarivate’s Derwent team conducted a comprehensive patent landscape study covering therapeutic uses of galectin-3 modulators and inhibitors, providing insights into innovation trends, assignees, filing breadth, invention strength, and remaining patent life. As a result, G3 was able to anticipate investor concerns, validate its IP strategy, identify licensing opportunities, and quickly file additional patent applications to strengthen its portfolio, helping attract investors and support future fundraising.

G3 Pharmaceuticals

Pieter Muntendam

President and Chief Executive Officer